Cardiac resynchronization therapy in patients with a prior history of atrial fibrillation: Insights from four major clinical trials

• DOI: 10.1111/jce.16022
• Publication Date: 2023-07-31T09:14:24Z
• Authors: Frederik Dalgaard; Marat Fudim; Sana M. Al‐Khatib; Daniel J. Friedman; William T. Abraham; John G. F. Cleland; Anne B. Curtis; Michael R. Gold; Valentina Kutyifa; Cecilia Linde; James Young; Fatima Ali‐Ahmed; Anthony Tang; Antonio Olivas‐Ma...; Lurdes Y. T. Inoue; Gillian D. Sanders
• Keywords: Clinical endpoint

Abstract Aims To investigate the association of cardiac resynchronization therapy (CRT) on outcomes among participants with and without a history atrial fibrillation (AF). Methods Individual‐patient‐data from four randomized trials investigating CRT‐Defibrillators (COMPANION, MADIT‐CRT, REVERSE) or CRT‐Pacemakers MIRACLE) were analyzed. Outcomes time to composite heart failure hospitalization all‐cause mortality alone. The CRT for patients AF was assessed using Bayesian‐Weibull survival regression model adjusting baseline characteristics. Results Of 3964 included, 586 (14.8%) had AF; 2245 (66%) CRT. Overall, reduced risk primary endpoint (hazard ratio [HR]: 0.69, 95% credible interval [CI]: 0.56–0.81). effect similar (posterior probability no interaction = 0.26) in (HR: 0.78, CI: 0.55–1.10) 0.67, 0.55–0.80). In these trials, did not reduce overall 0.82, 0.66–1.01) evidence 0.14) 1.09, 0.70–1.74) 0.70, 0.60–0.97). Conclusion statistically different AF, but this could reflect inadequate power. Our results call confirm benefit recipients AF.